Capping more than two years of stock-gyrating drama, Pfizer said it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another ...

I’m currently writing this through a haze of antihistamines that promise relief but instead deliver a stupor strong enough to ...